Phaseline

Companies › Prokidney

Prokidney: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Dec 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rilparencel (REACT)
Renal autologous cell therapy
–Phase 3Type 2 Diabetes MellitusDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05099770rilparencel (REACT)Phase 3Type 2 Diabetes MellitusGenitourinaryDec 2029

From the company's SEC filings

Cash of $75m on 2026-06-30; operating cash outflow about $166m a year; runway about 5 months at that burn, to Dec 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Urotronic Cisen Pharmaceutical Levee Medical YolTech Therapeutics Vera Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.